Drug Profile
Research programme: Epstein-Barr virus immunotherapy - Genocea Biosciences
Latest Information Update: 27 Mar 2023
Price :
$50
*
At a glance
- Originator Genocea Biosciences
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Epstein-Barr virus infections
Most Recent Events
- 20 May 2022 Discontinued - Preclinical for Epstein-Barr virus infections in USA (unspecified route) (Genocea Biosciences pipeline, March 2023)
- 28 Sep 2021 No recent reports of development identified for preclinical development in Epstein-Barr-virus-infections in USA
- 10 Aug 2017 Preclinical trials in Epstein-Barr virus infections in USA (unspecified route)